Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
S
Sophie M. Ernst
M
Mihaela Aldea
J
Jan H. von der Thüsen
A
Adrianus J. de Langen
E
Egbert F. Smit
M
Marthe S. Paats
J
Joachim G. J. V. Aerts
L
Laura Mezquita
S
Sanjay Popat
B
Benjamin Besse
J
Jordi Remon
C
Christian Rolfo
H
Hendrikus J. Dubbink
A
Anne-Marie C. Dingemans
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 22, Issue 5
Published
May 01, 2025
Pages
371-378
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (14)
S
Sophie M. Ernst
M
Mihaela Aldea
J
Jan H. von der Thüsen
A
Adrianus J. de Langen
E
Egbert F. Smit
M
Marthe S. Paats
J
Joachim G. J. V. Aerts
L
Laura Mezquita
S
Sanjay Popat
B
Benjamin Besse
J
Jordi Remon
C
Christian Rolfo
H
Hendrikus J. Dubbink
A
Anne-Marie C. Dingemans
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
Diana Romero
Jul 2026
10.1038/s41571-026-01169-4
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8